Soleus Capital Management, L.P. Travere Therapeutics, Inc. Transaction History

Soleus Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $3.26 Million - $4.82 Million	-213,000 Reduced 90.79%	21,600 $331,000
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $4.18 Million - $5.37 Million	234,600 New	234,600 $5.28 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $5.13 Million - $6.57 Million	-210,815 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $2.74 Million - $5.28 Million	210,815 New	210,815 $5.11 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.